Pre-made Ascrinvacumab benchmark antibody ( Whole mAb, anti-ACVRL1 therapeutic antibody, Anti-ACVRLK1/ALK-1/ALK1/HHT/HHT2/ORW2/SKR3/TSR-I Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-032
Pre-Made Ascrinvacumab biosimilar, Whole mAb, Anti-ACVRL1 Antibody: Anti-ACVRLK1/ALK-1/ALK1/HHT/HHT2/ORW2/SKR3/TSR-I therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Ascrinvacumab biosimilar, Whole mAb, Anti-ACVRL1 Antibody: Anti-ACVRLK1/ALK-1/ALK1/HHT/HHT2/ORW2/SKR3/TSR-I therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Duke University Medical Center;Fondazione IRCCS Istituto Nazionale dei Tumori;Pfizer;Suzhou Kintor Pharmaceuticals|
|Conditions Active||Age-related macular degeneration;Cancer;Liver Cancer|
|Conditions Discontinued||Colorectal cancer;Liver cancer;Solid tumours;Urogenital cancer|